Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-12 23:19 | 2025-06-10 | INSM | INSMED Inc | Bonstein Sara | Officer | OPT+S | $89.12 | 57,766 | $5,148,025 | 103,412 |
| 2025-06-13 03:42 | 2025-06-10 | CORT | CORCEPT THERAPEUTICS INC | Swisher Daniel N JR | Director | OPT+S | $70.61 | 2,200 | $155,342 | 0 |
| 2025-06-13 03:41 | 2025-06-10 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $72.42 | 20,000 | $1,448,474 | 5,487 |
| 2025-06-12 01:14 | 2025-06-10 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.40 | 169,600 | $67,993 | 33,162,968 |
| 2025-06-12 00:00 | 2025-06-10 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | OPT+S | $40.00 | 4,292 | $171,680 | 1,764 |
| 2025-06-12 00:32 | 2025-06-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $30.48 | 70,867 | $2,160,033 | 72,363 |
| 2025-06-12 01:37 | 2025-06-10 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | Officer | SELL | $10.01 | 3,300 | $33,017 | 102,117 |
| 2025-06-12 01:25 | 2025-06-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $20.34 | 6,667 | $135,574 | 303,309 |
| 2025-06-11 16:14 | 2025-06-09 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | OPT+S | $7.37 | 5,162 | $38,044 | 153,378 |
| 2025-06-11 23:59 | 2025-06-10 | PHIO | Phio Pharmaceuticals Corp. | Ferrara Robert L | Director | BUY | $2.42 | 2,500 | $6,050 | 15,666 |
| 2025-06-12 00:13 | 2025-06-09 | AKBA | Akebia Therapeutics Inc. | Malabre Richard C | Officer | OPT+S | $4.01 | 15,000 | $60,150 | 266,914 |
| 2025-06-12 03:34 | 2025-06-09 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% owner | BUY | $0.10 | 21,241,163 | $2,221,826 | 41,659,743 |
| 2025-06-12 00:35 | 2025-06-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Quart Barry D | Director | OPT+S | $30.35 | 27,448 | $833,000 | 12,546 |
| 2025-06-12 00:40 | 2025-06-09 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | OPT+S | $56.27 | 20,000 | $1,125,400 | 83,892 |
| 2025-06-11 23:15 | 2025-06-09 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $30.59 | 30,204 | $923,829 | 90,000 |
| 2025-06-12 02:44 | 2025-06-09 | TYRA | Tyra Biosciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $10.19 | 186,850 | $1,904,002 | 10,096,004 |
| 2025-06-12 00:00 | 2025-06-10 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $2.42 | 2,000 | $4,840 | 27,149 |
| 2025-06-12 00:04 | 2025-06-09 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Freund John Gordon | Director | OPT+S | $30.62 | 6,601 | $202,149 | 70,658 |
| 2025-06-12 04:40 | 2025-06-09 | ARDX | Ardelyx Inc. | MOTT DAVID M | Director | BUY | $3.69 | 200,000 | $737,260 | 2,696,871 |
| 2025-06-10 23:38 | 2025-06-06 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $79.82 | 200 | $15,964 | 63,101 |
| 2025-06-11 00:26 | 2025-06-09 | CNTX | Context Therapeutics Inc. | Lehr Martin A. | Director, Officer | BUY | $0.70 | 100,000 | $70,080 | 920,190 |
| 2025-06-11 00:23 | 2025-06-06 | CNTX | Context Therapeutics Inc. | Levit Alex C. | Officer | BUY | $0.58 | 20,000 | $11,520 | 29,000 |
| 2025-06-11 00:22 | 2025-06-06 | CNTX | Context Therapeutics Inc. | Minai-Azary Jennifer Lynn | Officer | BUY | $0.64 | 40,010 | $25,486 | 80,010 |
| 2025-06-10 23:05 | 2025-06-06 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.41 | 86,500 | $35,162 | 32,993,368 |
| 2025-06-11 03:07 | 2025-06-10 | MNKD | MANNKIND CORP | Binder Steven B. | Director | SELL | $4.00 | 64,085 | $256,340 | 925,258 |
| 2025-06-10 23:57 | 2025-06-06 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | SELL | $256.11 | 700 | $179,280 | 0 |
| 2025-06-10 23:56 | 2025-06-06 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $252.39 | 1,402 | $353,853 | 0 |
| 2025-06-10 23:55 | 2025-06-06 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $253.15 | 1,934 | $489,591 | 0 |
| 2025-06-10 23:45 | 2025-06-06 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Cramer Pamela J. | Officer | OPT+S | $68.05 | 7,031 | $478,435 | 19,209 |
| 2025-06-11 02:00 | 2025-06-09 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | Officer | OPT+S | $110.44 | 25,000 | $2,761,000 | 5,783 |
| 2025-06-10 23:39 | 2025-06-09 | ALKS | Alkermes plc. | Nichols Christian Todd | Officer | SELL | $31.52 | 6,667 | $210,143 | 86,208 |
| 2025-06-10 22:06 | 2025-06-09 | AYTU | AYTU BIOPHARMA, INC | Disbrow Jarrett | Officer | BUY | $1.50 | 16,666 | $24,999 | 29,462 |
| 2025-06-10 22:04 | 2025-06-09 | AYTU | AYTU BIOPHARMA, INC | Disbrow Joshua R. | Officer | BUY | $1.50 | 66,666 | $99,999 | 153,257 |
| 2025-06-11 00:00 | 2025-06-06 | CPRX | CATALYST PHARMACEUTICALS, INC. | MCENANY PATRICK J | Director | SELL | $26.09 | 200,000 | $5,217,340 | 4,281,702 |
| 2025-06-11 00:04 | 2025-06-09 | EOLS | Evolus, Inc. | White Albert G III | Director | BUY | $9.45 | 20,000 | $189,000 | 50,378 |
| 2025-06-11 00:00 | 2025-06-09 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $14.50 | 7,169 | $103,951 | 315,074 |
| 2025-06-10 23:43 | 2025-06-09 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $2.75 | 1,500 | $4,125 | 25,149 |
| 2025-06-11 02:28 | 2025-06-10 | CYRX | Cryoport, Inc. | ZECCHINI EDWARD J | Officer | OPT+S | $6.85 | 51,500 | $352,518 | 90,411 |
| 2025-06-11 02:25 | 2025-06-09 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Director | SELL | $7.06 | 5,622 | $39,673 | 77,089 |
| 2025-06-10 23:30 | 2025-06-09 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $325.37 | 12,000 | $3,904,496 | 8,118 |
| 2025-06-10 23:54 | 2025-06-06 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $252.77 | 5,127 | $1,295,946 | 0 |
| 2025-06-10 03:49 | 2025-06-06 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $50.00 | 2,996 | $149,800 | 56,725 |
| 2025-06-10 00:30 | 2025-06-05 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | OPT+S | $54.52 | 37,500 | $2,044,635 | 169,721 |
| 2025-06-10 03:18 | 2025-06-06 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | Officer | SELL | $10.01 | 2,900 | $29,021 | 103,864 |
| 2025-06-09 13:03 | 2025-06-05 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $1.40 | 21,000 | $29,400 | 734,460 |
| 2025-06-09 23:08 | 2025-06-05 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $1.74 | 10,100 | $17,545 | 23,323 |
| 2025-06-09 23:07 | 2025-06-05 | IMUX | IMMUNIC, INC. | Tardio Jason | Officer | BUY | $0.79 | 12,512 | $9,884 | 12,512 |
| 2025-06-10 00:19 | 2025-06-05 | RFL | Rafael Holdings, Inc. | JONAS HOWARD S | Director, Officer, 10% owner | BUY | $1.28 | 13,080,457 | $16,742,985 | 12,299,207 |
| 2025-06-07 00:56 | 2025-06-06 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | Officer | SELL | $6.76 | 10,470 | $70,777 | 378,245 |
| 2025-06-07 01:00 | 2025-06-06 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | Director, Officer | SELL | $6.76 | 50,676 | $342,570 | 1,303,761 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.